跳至主要内容
临床试验/KCT0012231
KCT0012231进行中(未招募)不适用

A Prospective, Multicenter, Investigator-Initiated Observational Study of Changes in JAK2 V617F Mutant Allele Burden in Patients with Polycythemia Vera Treated with Ropeginterferon

The Catholic University of Korea, Seoul St. Mary's Hospital0 个研究点目标入组 392 人开始时间: 2026年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
392

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational
观察模型
Cohort, Time Perspective : Prospective, Enrollment : 392, Biospecimen Retention : Collect & Archive- Sample with DNA, Biospecimen Description : Peripheral blood and DNA extracted from peripheral blood

入排标准

年龄范围
19(Year) 至 No Limit(—)
性别
All

入选标准

  • Adults over 18 years of age
  • Patients diagnosed with polycythemia vera according to the World Health Organization (WHO) criteria
  • Patients who are currently being treated with ropeginterferon after receiving at least one prescription, or who are scheduled to receive Ropeginterferon
  • Patients confirmed to have the JAK2 V617F mutation
  • Patients who have received sufficient explanation about participation in the study and voluntarily signed the Informed Consent Form (ICF)

排除标准

  • Patients who, in the investigator’s clinical judgment, are expected to have difficulty with follow-up or with completing study procedures
  • Patients who are deemed unsuitable for study participation due to significant comorbidities or other reasons
  • Patients for whom blood testing or blood sampling is medically contraindicated
  • Patients who discontinued Ropeginterferon more than 6 months prior and have no plan for re-administration
  • Patients with contraindications or hypersensitivity to Ropeginterferon

研究者

相似试验